PharmaFocus Today – Page 3 – media

$455 million! Boston Scientific ramps up its investment in heart pumps.

According to recent foreign media reports, Blackstone Life Sciences has signed a $455 million collaboration agreement with Boston Scientific to jointly fund the development of Boston Scientific’s next-generation micro heart pump system. It is understood that Boston Scientific’s next-generation micro heart pump system is part of the Vitalyst Temporary Percutaneous Transvalvular Circulatory Support System project. This device is designed to increase cardiac output, improve blood flow, and treat cardiogenic shock caused by acute myocardial infarction. Cardiogenic shock is a life-threatening condition in which the heart is unable to pump enough blood to supply the brain and other organs, manifesting as a heart attack or other heart problems. Despite advancements in treatment, its mortality rate remains high. According to Blackstone, the Vitalyst system was developed to address core unmet needs of critically ill cardiogenic patients, with the goal of improving efficacy, safety, and ease of use for physicians treating these patients. ...
- Source: drugdu
- 94
- November 10, 2026
Children’s cold medicine launched

Recently , Yiling Pharmaceutical issued an announcement stating that the National Medical Products Administration has officially approved the marketing of Lianhua Cold Granules for children, a Class 1.1 new traditional Chinese medicine , with the approval number Z20260006. In terms of indications, Lianhua Cold Granules for Children are mainly used to clear heat and relieve exterior symptoms, and to promote lung function and relieve heat. They are used for children aged 4-12 years with wind-heat colds , characterized by symptoms such as nasal congestion, runny nose with thick nasal discharge, sore throat, cough, headache, red tongue, thin yellow coating, and floating and rapid pulse. This means that it is not a simple reduced-dose version of adult cold medicine, but an innovative traditional Chinese medicine specifically for pediatric children with wind-heat as the main syndrome. In terms of R&D attributes, this product belongs to the innovative traditional Chinese medicine guided by ...
- Source: drugdu
- 81
- November 10, 2026
Ribo Life Science files EU Phase I clinical trial application for dual-target siRNA SR122

On November 10, Ribo Life Science (06938.HK) announced in a voluntary disclosure that it had filed a Phase I clinical trial application in the European Union for its in-house candidate SR122 injection. SR122 is a GalNAc-conjugated small interfering RNA (siRNA) therapy that targets both ApoC3 and PCSK9. It is being developed for dyslipidemia, including severe hypertriglyceridemia and mixed dyslipidemia. The planned Phase I study will be randomized and placebo-controlled. It will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered SR122 in healthy volunteers. Source: https://finance.eastmoney.com/a/202611103926814664.html
- Source: drugdu
- 100
- November 10, 2026
China accepts Shanghai RAAS’s SR604 clinical trial application for Glanzmann thrombasthenia

On November 9, Shanghai RAAS announced that China’s National Medical Products Administration had accepted a clinical trial application for SR604 injection as a prophylactic treatment for Glanzmann thrombasthenia. SR604 is a humanized monoclonal antibody that binds human activated protein C with high affinity and selectively inhibits its anticoagulant activity. For the prevention of bleeding in hemophilia A and B, SR604 met its prespecified primary endpoint in Phase II, and key data were presented at an international conference. Phase III is underway. Studies on the prevention of bleeding in congenital factor VII deficiency and von Willebrand disease are both in Phase II. In a separate public notice, China’s Center for Drug Evaluation proposed including SR604 injection in the extended pilot program supporting innovative drug development for rare diseases. Source: https://finance.eastmoney.com/a/202611093926395123.html
- Source: drugdu
- 70
- November 10, 2026
Boyi Group completes nearly 100 million RMB Series B financing

Recently, Changzhou Boyi Technology Group Co., Ltd. (“Boyi Group”) announced the completion of its Series B1 and B2 financing rounds. Series B1 was exclusively invested by BGI Songhe, while Series B2 was led by Zero2IPO Investment, with participation from Jiangsu Changzhou High-end Functional Materials Industry Special Fund of Funds (Limited Partnership), Jiangsu Huaian Digital Manufacturing Industry Special Fund of Funds (Limited Partnership) under Huaian Venture Capital Group, existing shareholders Jinyu Maowu and BGI Songhe, and strategic investors. The total financing amount for Series B1 and B2 rounds is nearly RMB 100 million. The funds raised will primarily be used for the research and development of new materials and intelligent protein purification systems, as well as accelerating global commercial promotion and implementation. Founded in January 2022, Boyi Group owns three major brands: Tiandi Renhe, Boyi Bio, and ACE. Its business covers high-performance bio-purification packing materials, high-efficiency life science research reagents, high-standard ...
- Source: drugdu
- 84
- November 6, 2026
Net profit surges by 588%! A century-old traditional Chinese medicine brand successfully shifts gears.

Against the backdrop of overall pressure on the traditional Chinese medicine industry in 2026, Jiuzhitang stood out with a third-quarter report showing a year-on-year increase of over 588% in net profit attributable to the parent company . A rare “double increase” report card In the first three quarters of 2026, Jiuzhitang achieved operating revenue of RMB 2.186 billion, a year-on-year increase of 34.34%; net profit attributable to the parent company reached RMB 304 million, a year-on-year increase of 100.33%; and net profit after deducting non-recurring gains and losses increased by 110.63%, outpacing the growth rate of net profit attributable to the parent company, indicating that the growth was mainly driven by the main business. Even more noteworthy is the performance in the third quarter: net profit attributable to the parent company was 53.3756 million yuan, a year-on-year increase of 588.01%, and the gross profit margin rose by 1.72 percentage points ...
- Source: drugdu
- 89
- November 6, 2026
Singapore approves CMS’s ruxolitinib phosphate cream for nonsegmental vitiligo

China Medical System (00867.HK) announced on November 4 that Singapore’s Health Sciences Authority had approved Lumirix® (ruxolitinib phosphate cream) for nonsegmental vitiligo with facial involvement in adults and adolescents aged 12 and older. According to the company, it was Singapore’s first and, at the time, only topical prescription treatment that directly targets the underlying disease mechanism. Source: http://finance.eastmoney.com/a/202611043922060662.html
- Source: drugdu
- 98
- November 6, 2026
China accepts United Laboratories’ semaglutide injection filing for weight management

The United Laboratories (03933) announced on November 4 that China’s NMPA had accepted a marketing application from its wholly owned Zhuhai biologics subsidiary for semaglutide injection for weight management. The article describes uses of semaglutide injection in glycemic control in type 2 diabetes, long-term weight management in people with obesity or overweight, and reducing the risk of related cardiovascular events. The United Laboratories said the filing broadens its planned indications for the product. Its GLP-1 pipeline includes both innovative drugs and biosimilars. Source: http://finance.eastmoney.com/a/202611053922758066.html
- Source: drugdu
- 126
- November 6, 2026
Daridorexant receives US FDA Breakthrough Therapy designation for pediatric insomnia

According to Simcere Pharmaceutical on November 5, the US FDA granted daridorexant Breakthrough Therapy designation for insomnia disorder in children and adolescents aged 10 to 18. The article cites study findings that the 50 mg dose showed a safety profile similar to placebo, with no drug abuse-related adverse events reported during treatment. Daridorexant is a dual orexin receptor antagonist that suppresses wake-promoting signaling by blocking orexin A and B from binding to their receptors. In November 2022, Simcere obtained exclusive development and commercialization rights in Greater China from Switzerland’s Idorsia. China approved the drug in June 2025 for adults with insomnia characterized by difficulty falling or staying asleep. Source: http://finance.eastmoney.com/a/202611053923706422.html
- Source: drugdu
- 102
- November 6, 2026
Menovo subsidiary passes first US FDA on-site inspection for tildipirosin API

Menovo (603538) disclosed on November 6 that its controlled subsidiary, Xuancheng Menovo, received a US FDA inspection report on November 4 confirming that it had passed its first FDA on-site inspection for tildipirosin API. The preapproval cGMP inspection ran from June 22 to 26, 2026, and covered quality, materials, manufacturing, facilities and equipment, packaging and labeling, and laboratory controls. The company said the inspection outcome would support its international expansion. Menovo develops, manufactures and sells specialty APIs and finished dosage forms. In the first nine months of 2026, revenue rose 29.00% year on year to RMB 1.441 billion, and net profit attributable to shareholders rose 8.54% to RMB 104 million. Source: http://finance.eastmoney.com/a/202611063924413520.html
- Source: drugdu
- 97
- November 6, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.